Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report

• Published in: Journal of medical case reports Vol. 4; no. 1; p. 141
• Main Authors: Oertelt-Prigione, Sabine, Crosignani, Andrea, Gallieni, Maurizio, Vassallo, Emanuela, Podda, Mauro, Zuin, Massimo
• Format: Journal Article
• Language: English
• Published: England BioMed Central Ltd 19-05-2010; BioMed Central; BMC
• Subjects: ACE inhibitors; Case report; Case studies; Complications and side effects; Drug therapy; Drug therapy, Combination; Encephalopathy; Liver cirrhosis; Patient outcomes; Proteinuria; Risk factors
• ISSN: 1752-1947; 1752-1947
• DOI: 10.1186/1752-1947-4-141

A combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers has been used to control proteinuria, following initial demonstration of its efficacy. However, recently concerns about the safety of this therapy have emerged, prompting several authors to urge for caution in its use. In the following case report, we describe the occurrence of a serious and unexpected adverse drug reaction after administration of a combination of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers to a patient with nephrotic syndrome and liver cirrhosis with severe portal hypertension.
We administered this combination therapy to a 40-year-old Caucasian man with liver cirrhosis in our Hepatology Clinic, given the concomitant presence of glomerulopathy associated with severe proteinuria. While the administration of one single drug appeared to be well-tolerated, our patient developed severe acute encephalopathy after the addition of the second one. Discontinuation of the therapy led to the disappearance of the side-effect. A tentative rechallenge with the same drug combination led to a second episode of acute severe encephalopathy.
We speculate that this adverse reaction may be directly related to the effect of angiotensin II on the excretion of blood ammonia. Therefore, we suggest that patients with liver cirrhosis and portal hypertension are at risk of developing clinically relevant encephalopathy when angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker combination therapy is administered, thus indicating the need for a careful clinical follow-up. In addition, the incidence of this serious side-effect should be rigorously evaluated in all patients with liver cirrhosis administered with this common treatment combination.